Treosulfan
Appearance
Clinical data | |
---|---|
Other names | 1,2,3,4-Butanetetrol, 1,4-dimethanesulfonate, Threitol 1,4-dimethanesulfonate, Threitol 1,4-bismethanesulfonate; L-Threitol 1,4-bis(methanesulfonate); Ovastat; Threosulphan; Treosulphan; Tresulfan |
AHFS/Drugs.com | International Drug Names |
Routes of administration | Oral, IV |
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
UNII | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.005.529 |
Chemical and physical data | |
Formula | C6H14O8S2 |
Molar mass | 278.30056 g·mol−1 g·mol−1 |
Melting point | 101.5 to 105 °C (214.7 to 221.0 °F) |
(what is this?) (verify) |
Treosulfan is a substance that is being studied in the treatment of cancer.[1] It belongs to the family of drugs called alkylating agents. It has been used mainly as a substitute of busulfan in frail patients, as the side effects and toxicity are supposedly less severe.
References
- ^ Schmittel A, Schmidt-Hieber M, Martus P, et al. (December 2006). "A randomized phase II trial of gemcitabine plus treosulfan versus treosulfan alone in patients with metastatic uveal melanoma". Ann. Oncol. 17 (12): 1826–9. doi:10.1093/annonc/mdl309. PMID 16971664.
External links
- Treosulfan entry in the public domain NCI Dictionary of Cancer Terms
This article incorporates public domain material from Dictionary of Cancer Terms. U.S. National Cancer Institute.